Oestrogen-mediated phosphorylation and stabilization of BRCA2 protein in breast

Journal of Pathology

Volumn 217, Issue 3, 2009, Pages 380-388

  Malone, J L ^a   Nelson, A C ^a   Lieberman, R ^a   Anderson, S ^a   Holt, J T ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

BRCA2; Breast cancer; Oestrogen; Phosphorylation

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE; CYCLOHEXIMIDE; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; ROSCOVITINE; SMALL INTERFERING RNA; TAMOXIFEN; ESTROGEN;

ARTICLE; BREAST; CELL CYCLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; BREAST TUMOR; COMPARATIVE STUDY; DNA REPAIR; FEMALE; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BRCA2 PROTEIN; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA REPAIR; ESTROGENS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 60549106669     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2458     Document Type: Article

References (22)

1. Kurbel S. Selective reduction of ER positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers. Med Hypoth 2005;64:1182- 1187.
2. Hedenfalk L, Duggan D, Chen Y. Gene expression profiles in hereditary breast cancer. N Engt J Med 2001;344:539-548.
3. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4:814-819.
4. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006;9:121-132.
5. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT. Estro gen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004;10:2029-2034.
6. Clarke RB, Spence K, Anderson E, Howell A, Okana H, Potten CS. A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol 2005;277:443-456.
7. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, et al. Purification and unique properties of mammary epithelial stem cells. Nature 2006;439:993-997.
8. Razandi M, Pedram A, Rosen EM, Levin ER. BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol Cell Biol 2004;24:5900-5913.
9. King MC, Marks JH, Mandell JB. The New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-646.
10. Esashi F, Christ N, Gannon J, Liu Y, Hunt T, Jasin, et al. CDK- dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 2005;434:598-604.
11. Boonyarantanakornit V, Scott MP, Ribon V, Sherman L, Anderson SM, Mailer JM, et al. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-scr family tyrosine kinases. Mol Cell 2001;8:269-280.
12. Improta-Brears T, Whorton AR, Codazzi F, York JD, Meyer T, McDonnell DP. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc Natl Acad Sci USA 1999;96:4686-4691.
13. Rajan JV, Marquis ST, Gardner HP, Chodosh LA. Developmental expression of Brca2 colocalizes with Brcal and is associated with proliferation and differentiation in multiple tissues. Dev Biol 1997;184:385- 401.
14. Rajan JV, Wang M, Marquis ST, Chodosh LA. Brca2 is coordinately regulated with Brcal during proliferation and differ entiation in mammary epithelial cells. Proc Natl Acad Sci USA 1996;93:13078-13083.
15. Foster JS, Henley DC, Bukovsky A, Seth P, Wimalasena J. Multifaceted regulation of cell cycle progression by estrogen: regulation of CDK inhibitors and cdc25A independent of cyclin Dl-cdk4 function. Mol Cell Biol 2001;21:794-810.
16. Foster JS, Fernando IR, Ishida N, Nakayama KI, Wimalasena J. Estrogens down-regulate p27Kipl in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. J Biol Chem 2003;278:41355- 41366.
17. Maude SL, Enders GH. Cdk inhibition in human cells compro mises chkl function and activates a DNA damage response. Can cer Res 2005;65:780-786.
18. Fritah A, Saucier C, Mester J, Redeuilh G, Sabbah M. p21WAFl/CIP1 selectively controls the transcriptional activity of estrogen receptor α. Mol Cell Biol 2005;25:2419-2430.
19. Moro L, Arbini AA, Marra E, Greco M. Upregulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation. J Biol Chem 2006;281:22100-22107.
20. Long X, Nephew KP. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-α. J Biol Chem 2006;281:9607-9615.
21. Senderowicz AM. Small-molecule cyclin-dependent kinase modu lators. Oncogene 2003;22:6609-6620.
22. Katzenellenbogen BS, Kendra, Norman MJ, Berthois Y. Prolifer ation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 1987;47:4355-4360.